NCT03207542 2018-07-26
Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
1 trialsMalignant Neoplasms Stated as Primary Lymphoid Haematopoietic × daratumumab × Other neoplasm × Clear all